Reports On Company: kilpest
| Kilpest is available at a discount of ~51% to the average P/E ratio of two prominent diagnostic players. Buy for 43% upside: Nuvama | |
| Company: | kilpest |
| Brokerage: | Nuvama |
| Date of report: | September 11, 2023 |
| Type of Report: | Initiating Coverage |
| Recommendation: | Buy |
| Upside Potential: | 43% |
| Summary: | Kilpest India (KLPI) has seen multiple transformations in the last ~50 years of existence. Based in Bhopal, it started with agrochemicals in 1972 and forayed into the niche molecular diagnostics business in FY10 through its subsidiary 3B Black Bio Biotech India |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | |